Effect of Neurotensin on Dopamine and Muscarinic Acetylcholine Receptors in the Rat Striatum

  • Rie Miyoshi
  • Shozo Kito
  • Akiko Tanaka
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)


Neurotensin (NT) is a tridecapeptide first isolated and sequenced from bovine hypothalamus in 1973 (1). This peptide has a wide distribution within central and peripheral tissues where it is present in both neuronal and endocrine structures (2). In the mammalian central nervous system, NT has been established as a candidate of neurotransmitter/neuromodulator. NT-containing fibers (3,4) and NT receptors (5,6) have been observed in high density within the striatum. An interaction between dopamine and NT has been well demonstrated in the nigro-striatal neuronal pathway. For instance, it has been reported that NT receptors are not only located on dopaminergic perikarya and dendrites (7) but also on dopaminegic nerve terminals (8). In addition, NT facilitates endogenous or K+-evoked dopamine release (9,10,11). From receptor binding assay, it has been observed that NT decreases the affinity of D2 receptor agonist binding (12). On the other hand, NT dose not modulate the binding characteristics of 3H-spiperone, which is a D2 receptor antagonist (13).


Dopamine Receptor Agonist Binding High Affinity Binding Site Saturation Experiment Antagonist Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Carraway and S. E. Leeman, The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami, J. Biol. Chem., 248: 6854 (1973)PubMedGoogle Scholar
  2. 2.
    C. B. Nemeroff, D. Luttinger, and A. J. Prange, Neurotensin and bombesin, in: “Handbook of Psychopharmacology”, L. L. Iversen, S. D. Iversen, and S. H. Snyder, eds., Plenum Press, New York, p. 363 (1983)Google Scholar
  3. 3.
    G. R. Uhl, M. J. Kuhar, and S. H. Snyder, Neurotensin: immunohistochemical localization in rat central nervous system, Proc. Natl. Acad. Sci., 74: 4059 (1977)PubMedCrossRefGoogle Scholar
  4. 4.
    M. Goedert, P. W. Mantyh, P. C. Emson, and S. P. Hunt, Inverse relationship between neurotensin receptors and neurotensin-like immunoreactivity in cat striatum, Nature, 307: 543 (1984)PubMedCrossRefGoogle Scholar
  5. 5.
    W. S. III Young and M. J. Kuhar, Neurotensin receptor localization by light microscopic autoradiography in rat brain, Brain Res., 206: 273 (1981)PubMedCrossRefGoogle Scholar
  6. 6.
    M. Goedert, K. Pittaway, B. J. Williams, and P. C. Emson, Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution, Brain Res., 304: 71 (1984)PubMedCrossRefGoogle Scholar
  7. 7.
    J. M. Palacios and M. J. Kuhar, Neurotensin receptors are located on dopamine-containing neurones in rat midbrain, Nature, 294: 587 (1981)PubMedCrossRefGoogle Scholar
  8. 8.
    M. Goedert, K. Pittaway, and P. C. Emson, Neurotensin receptors in the rat striatum: lesion studies, Brain Res., 299: 164 (1984)PubMedCrossRefGoogle Scholar
  9. 9.
    Y. Okuma, Y. Fukuda, and Y. Osumi, Neurotensin potentiates the potassium-induced release of endogenous dopamine from rat striatal slices, Eur. J. Pharmacol., 93: 27 (1983)PubMedCrossRefGoogle Scholar
  10. 10.
    M. E. Quidt and P. C. Emson, Neurotensin facilitates dopamine release in vitro from rat striatal slices, Brain Res., 274: 376 (1983)PubMedCrossRefGoogle Scholar
  11. 11.
    D. Jiang, D. Feng, L. Zhu, and Y. Cheng, Neurotensin potentiates the endogenous dopamine release from striatal synaptosomes of rat, Life Sci., 43: 27 (1988)PubMedCrossRefGoogle Scholar
  12. 12.
    G. Euler and K. Fuxe, Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes, Acta Physiol. Scand., 131: 625 (1987)Google Scholar
  13. 13.
    C. B. Nemeroff, D. Luttinger, D. E. Hernandez, R. B. Mailman, G. A. Mason, S. D. Davis, E. Widerlov, G. D. Frye, C. A. Kilts, K. Beaumont, G. R. Breese, and A. J. Prange, Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies, J. Pharmacol. Exp. Ther., 225: 337 (1983)PubMedGoogle Scholar
  14. 14.
    S. E. Leff and I. Creese, Dopamine receptors re-explained, Trends Pharmacol. Sci., 463 (1983)Google Scholar
  15. 15.
    J. C. Stoof and J. W. Kebabian, Two dopamine receptors: biochemistry, physiology and pharmacology, Life Sci., 35: 2281 (1984)PubMedCrossRefGoogle Scholar
  16. 16.
    L. C. lorio, A. Barnett, F. H. Leits, V. P. Houser, and C. A. Korduba, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J. Pharmacol. Exp. Ther., 226: 462 (1983)Google Scholar
  17. 17.
    K. M. O’Boyle and J. L. Waddington, Selectie and stereospecific interactions of R-SK & F 38393 with (H)piflutixol but not (H)spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390, Eur. J. Pharmacol., 98: 433 (1984)PubMedCrossRefGoogle Scholar
  18. 18.
    E. Szigethy, G. L. Wenk, and A. Beaudet, Anatomical substrate for neurotensin-acetylcholine interactions in the rat basal forebrain, Peptides, 9: 1227 (1989)CrossRefGoogle Scholar
  19. 19.
    D. Maith e-Sorenssen, P. L. Wood, D. L. Cheney, and E. Costa, Modulation of the turnover rate of acetylcholine in rat brain by intraventricular injections of thyrotropin-releasing hormone, somatostatin, neurotensin and angiotensin II, J. Neurochem., 31: 685 (1978)CrossRefGoogle Scholar
  20. 20.
    P. Seeman, C. Ulpian, D. Grigoriadis, I. Pri-Bar, and 0. Buchman, Conversion of dopamine D1 receptors from high to low affinity for dopamine, Biochem. Pharmacol., 34: 151 (1985)Google Scholar
  21. 21.
    C. B. Nemeroff, D. E. Hernandez, D. Luttinger, P. W. Kalivas, and A. J. Prange, Interactions of neurotensin with brain dopamine systems, Ann. N. Y. Acad. Sci., 400: 330 (1982)PubMedCrossRefGoogle Scholar
  22. 22.
    G. R. Uhl and M. J. Kuhar, Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra, Nature, 309: 350 (1984)PubMedCrossRefGoogle Scholar
  23. 23.
    S. M. Simasko and G. A. Weiland, Effect of neurotensin, substance P and TRH on the regulation of dopamine receptors in rat brain, Eur. J. Pharmacol., 106: 653 (1985)CrossRefGoogle Scholar
  24. 24.
    J. C. Stoof and J. W. Kebabian, Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum, Nature, 294: 366 (1981)PubMedCrossRefGoogle Scholar
  25. 25.
    J. R. Walters, D. A. Bergstrom, J. H. Carlson, T. N. Chase, and A. R. Braun, D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects, Science, 236: 719 (1987)PubMedCrossRefGoogle Scholar
  26. 26.
    O. Gershanik, R. E. Heikkila, and R. C. Duvoisin, Behavioral correlations of dopamine receptor activation, Neurology, 33: 1489 (1983)PubMedCrossRefGoogle Scholar
  27. 27.
    D. M. Jackson and M. Hashizume, Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SK&F 38393, Psychopharmacol., 90: 147 (1986)Google Scholar
  28. 28.
    M. Goedert, K. Pittaway, B. J. Williams, and P. C. Emson, Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution, Brain Res., 304: 71 (1984)PubMedCrossRefGoogle Scholar
  29. 29.
    K. S. Kanba and E. Richelson, Comparison of the stimulation of inositol phospholipid hydrolysis and of cyclic GMP formation by neurotensin, some of its analogs, and neuromedin N in neuroblastoma clone N1E-115, Biochem. Pharmacol., 36: 869 (1987)Google Scholar
  30. 30.
    M. Goedert, R. D. Pinnock, C. P. Downes, P. W. Mantyh, and P. C. Emson, Neurotensin stimulates inositol phospholipid hydrolysis in rat brain slices, Brain Res., 323: 193 (1984)PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Rie Miyoshi
    • 1
  • Shozo Kito
    • 1
  • Akiko Tanaka
    • 1
  1. 1.Third Department of Internal MedicineHiroshima University School of MedicineHiroshima 734Japan

Personalised recommendations